Tremelimumab (Imjudo)
Dilution requiredFull monograph review pending
U.S. label preparation
Imjudo · Dilution required
- Preparation
- Dilute the dose in 0.9% sodium chloride or 5% dextrose to 0.1-10 mg/mL.
- Administration and handling
- Infuse over 60 minutes. Follow the regimen-specific sequence with the other agents.
Product and source details
AstraZeneca Pharmaceuticals LP · BLA761289
Product NDC: 0310-4505, 0310-4535
SPL effective 2026-08-31 | SPL version 15. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.